TITLE:
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

CONDITION:
Non Small Cell Lung Carcinoma

INTERVENTION:
TLK286 (Telcyta) HCl for Injection

SUMMARY:

      The purpose of this study is to determine if TLK286(Telcyta) is more effective than
      gefitinib (Iressa) in the treatment of non-small cell lung cancer.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of non-small cell lung cancer

          -  Non-small cell lung cancer that is not curable with surgery, radiation, or combined
             modality chemoradiation

          -  Failed two prior chemotherapy regimens which must have included platinum

          -  Measurable disease

        Exclusion Criteria:

          -  Treatment with more than two prior chemotherapy regimens

          -  History of bone marrow transplantation or stem cell support

          -  Pregnant or lactating women

          -  Known history of prior gefitinib therapy

          -  Known history of prior TLK286 therapy
      
